Creat Group, a Beijing investment firm, has bid to acquire German blood plasma products maker Biotest for $1.3 billion (including debt). Located south of Frankfurt, Biotest makes plasma-based products and biological drugs. It is majority owned by the founding family corporation, which will have the final say in whether the acquisition will be completed. Last year, Creat paid just over $1 billion to acquire Bio Products Lab, a UK blood plasma company.
